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ABSTRACT
The skeletal muscle regeneration occurs due to the presence of tissue speciﬁc stem cells - satellite
cells. These cells, localized between sarcolemma and basal lamina, are bound to muscle ﬁbers and
remain quiescent until their activation upon muscle injury. Due to pathological conditions, such as
extensive injury or dystrophy, skeletal muscle regeneration is diminished. Among the therapies
aiming to ameliorate skeletal muscle diseases are transplantations of the stem cells. In our previous
studies we showed that Sdf-1 (stromal derived factor ¡1) increased migration of stem cells and
their fusion with myoblasts in vitro. Importantly, we identiﬁed that Sdf-1 caused an increase in the
expression of tetraspanin CD9 - adhesion protein involved in myoblasts fusion. In the current study
we aimed to uncover the details of molecular mechanism of Sdf-1 action. We focused at the Sdf-1
receptors - Cxcr4 and Cxcr7, as well as signaling pathways induced by these molecules in primary
myoblasts, as well as various stem cells - mesenchymal stem cells and embryonic stem cells, i.e. the
cells of different migration and myogenic potential. We showed that Sdf-1 altered actin
organization via FAK (focal adhesion kinase), Cdc42 (cell division control protein 42), and Rac-1 (Ras-
Related C3 Botulinum Toxin Substrate 1). Moreover, we showed that Sdf-1 modiﬁed the
transcription proﬁle of genes encoding factors engaged in cells adhesion and migration. As the
result, cells such as primary myoblasts or embryonic stem cells, became characterized by more
effective migration when transplanted into regenerating muscle.
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Introduction
The skeletal muscle regeneration occurs due to the presence
of stem cells called satellite cells (SCs) that are localized
between sarcolemma and basal lamina. The role of SCs in
25 skeletal muscle repair is unquestionable [reviewed in ref.1].
Unfortunately, due to aging, extensive damages or various
pathological states, for example muscular dystrophy, muscle
reconstruction is diminished.2-4 Stem cells transplantation
belongs to the therapeutic approaches aiming to improve
30 muscle regeneration [reviewed in5]. In the initial studies,
focusing on the skeletal muscle cell therapies, SCs and pri-
mary myoblasts, due to their natural function, were the ﬁrst
choice of cells tested [reviewed in6,7]. Under physiological
conditions, after muscle injury, SCs become activated what
35 leads to the cell cycle re-entry, proliferation, and ﬁnally their
differentiation into myoblasts that fuse and reconstruct
myotubes and then muscle ﬁbers. In the 80s of XX century
Partridge and collaborators documented that wild-type
myoblasts injected to muscle of dystrophic mice (mdxmice)
40were able to reconstruct muscle ﬁbers and restore the dys-
trophin synthesis.8 As demonstrated later, the improvement
in the skeletal muscle regeneration was observed after trans-
plantation of undifferentiated, puriﬁed satellite cells popula-
tion, rather than satellite cells derived myoblasts.9,10 In the
4590s many clinical trials based on the model described by
Partridge were conducted, however, the results were not
satisfactory [reviewed in6,11]. Transplanted cells were able to
participate in the muscle regeneration and partially restore
dystrophin expression but no functional long-term
50improvement was observed.12-14
The most important obstacles in myoblast transplanta-
tion include speciﬁc immune response against transplanted
cells, limited migration within the muscle, and massive apo-
ptosis of transplanted cells [reviewed in refs.7,15,16]. The
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55 limited migration ability of transplanted myoblasts was
shown in many studies.17-20 Thus, many lines of evidence
documented that injected myoblasts accumulate within the
site of injection and only few reports showed that they could
migrate up to 1 cm in depth from the monkey (Macaca
60 mulata) muscle surface.21 Importantly, co-injected growth
factors such as bFGF (basic ﬁbroblast growth factor) and
IGF-1 (insulin like growth factor), improved migration of
monkey (Macaca mulata) myoblasts transplanted into
biceps brachii. However, myoﬁbers formed with the partici-
65 pation of these cells were detectable only near the injection
site. Moreover, analyzed myoblasts were not able to fuse
with undamagedmuscle ﬁbers, regardless of the growth fac-
tors used.22 In our own studies we showed that the Sdf-1
could improve migration of satellite cell derived myoblasts
70 and C2C12 myoblasts in vitro in metalloproteinase (MMP)
dependent manner.23 We also documented that Sdf-1 treat-
ment enhanced embryonic stem cells (ESCs) and bonemar-
row derived mesenchymal stem cells (BM-MSC) migration
and fusion with myoblasts in vitro, what was connected
75 with the increase in tetraspanin CD9 expression.24
In the current study we investigated which molecular
pathways induced by Sdf-1 lead to the increased migra-
tion. We hypothesized that stimulation of transplanted
cells migration using Sdf-1 improves their ability to par-
80 ticipate in muscle repair. To verify this hypothesis we
analyzed various stem cell populations - mouse primary
myoblasts derived from SCs, human mesenchymal stem
cells isolated from umbilical cord connective tissue, i.e.,
Wharton’s jelly (WJ- MSCs), and mouse ESCs. Our
85 choice based on the previous studies in that we
documented that these stem cells ale able to undergo
myogenic differentiation and also to participate in the
skeletal muscle regeneration.24-26
Multipotent mesenchymal stem cells (MSCs) could be
90 derived from different sources, such as bone marrow, adi-
pose tissue,Wharton jelly (umbilical cord connective tissue),
umbilical cord blood, skin, dental pulp, spleen, lung, and
also skeletal muscles [reviewed in refs.27,28]. Various popu-
lations ofmesenchymal stem cells were able to improve skel-
95 etal muscle reconstruction.29-31 Myogenic differentiation of
the pluripotent stem cells, such as embryonic stem cells
(ESCs), which are characterized by unlimited potential to
proliferate and ability to differentiate into any given tissue,
has been also documented [reviewed in refs.32,33]. An efﬁ-
100 cient protocol allowing derivation of myoblasts from ESCs,
based on the supplementation of culture medium with fac-
tors inducing mesoderm formation and myogenic differen-
tiation, was proposed only recently and obtained myoblasts
were tested both in vitro and in vivo.34 Cells derived from
105 ESCs when transplanted into tibialis anterior muscles of
mdxmice were able to formmuscle ﬁbers and also to differ-
entiate into Pax7-expressing cells that resembled SCs.34
However, methods improving homing of these cells to the
site of the injury via improvement of their migration are still
110not readily available.
In the current study we compared the reaction of pri-
mary myoblasts, WJ-MSC, as well as ESCs to Sdf-1 treat-
ment, which – as we previously shown - is a potent
factor improving skeletal muscle regeneration.23,24 First
115we analyzed changes in transcription proﬁle and the sig-
naling pathways engaged in stem cells response to Sdf-1
treatment. Next, we concentrated on the role of Sdf-1
receptors i.e. CXCR7 and CXCR4 in stem cells migration
both in vitro and in vivo. Then, we examined if Sdf-1
120pretreatment of stem cells with Sdf-1 or co-injection of
these cytokine could improve participation of tested cells
in the skeletal muscle regeneration.
Materials and methods
All the experiments were performed with the approval of
125Local Ethical Commission No 1 in Warsaw – permission
no 240/2012.
Cells cultures
Satellite cells – derived myoblasts (primary myoblasts)
Satellite cells were isolated from the gastrocnemius muscles
130of 3months old C57Bl6Nmalemice carrying the lacZ trans-
gene in the ROSA26 locus. Mice were sacriﬁced by cervical
dislocation. Muscle ﬁbers were isolated according to previ-
ously described protocol.35 Brieﬂy, muscles were dissected
and digested with 0.2% collagenase type I (Sigma-Aldrich)
135in Dulbecco’s modiﬁed Eagle’s medium (DMEM, Life Tech-
nologies) at 37C in 5% CO2 for 60min. Next, single muscle
ﬁbers were transferred to DMEM containing 10% horse
serum (HS, Life Technologies) and 1% penicillin/streptomy-
cin antibiotics (AB, Life Technologies). Suspension of mus-
140cle ﬁbers was passed through a syringe needle (21G) and
cleared by ﬁltration through 40 mm cell strainer. Obtained
satellite cells were plated in 6-well culture dishes coated with
Matrigel Matrix Growth Factor Reduced (BD Biosciences).
Primary myoblasts were maintained in so called “growth
145medium,” i.e., DMEM supplemented with 20% fetal bovine
serum (FBS), 10% HS, 0.5% chicken embryo extract (CEE,
Life Technologies) and 1% AB.
Mesenchymal stem cells derived from wharton
(WJ-MSCs)
150WJ-MSCs were kindly provided by prof. Zygmunt Pojda
(Department of Molecular and Translational Oncology,
Maria Sk»odowska-Curie Memorial Cancer Center and
Institute of Oncology, Warsaw, Poland). WJ-MSCs were
seeded and cultured in DMEM (Life Technologies) supple-
155mented with 15% heat inactivated FBS (hiFBS) and 1% AB.
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Mouse embryonic stem cells (ESCs)
ESCs constitutively expressing histone H2B-GFP were pro-
vided by Dr. Kat Hadjantonakis.36 Mitomycin-inactivated
mouse embryonic ﬁbroblasts (MEFs), that served as feeder
160 layer for ES cells, were plated on 1% gelatin coated culture
dishes (Sigma-Aldrich) and cultured in DMEM supple-
mented with 10% FBS and 1% AB. Twenty four hours later
ESCs were seeded onto the inactivated MEFs and cultured
in knockout DMEM (Life Technologies) supplemented
165 with 10% serum replacement (SR, Life Technologies),
0.1 mM nonessential amino acids (Sigma-Aldrich), 2 mM
L-glutamine (Life Technologies), 0.1 mM b-mercaptoetha-
nol (Sigma-Aldrich), 1%AB, and 500U/ml leukemia inhibi-
tory factor (LIF, Chemicon). Prior to transfection with
170 siRNA, ESCs were separated fromMEFs by pre-plating and
cultured in cultured dishes coated with 10%Matrigel Matrix
Growth Factor Reduced (BD Biosciences) in DMEM until
the time of further manipulations.
Morphological analyses
175 The morphology of primary myoblasts, WJ-MSCs, and
ESCs was analyzed using Nikon Eclipse TE200 micro-
scope equipped with Hoffman contrast.
Cells transfection
Primary myoblasts, WJ-MSCs, and ESCs were plated
180 into culture dishes and after reaching 50-60% of conﬂu-
ency transfected with Silencer Select Pre-designed siRNA
(Life Technologies) complementary to mRNAs encoding
either Cxcr4 (ID:s64091) or Cxcr7 (ID:s64124). Appro-
priate negative control siRNA was used according to
185 manufacturer’s recomendation. siRNA duplexes were
diluted in DMEM to 100 pmol concentration and Lipo-
fectamine RNAiMAX (Life Technologies) was added
according to manufacturer’s instructions. The Sdf-1
(10 ng/ml) was added 24 h after transfection. The cells
190 were collected 48 h post-Sdf-1 treatment and processed
either for mRNA isolation, followed by qRT-PCR,
immunolocalization, Western blotting, G-LISA or for
transplantation into injured and regenerating gastrocnie-
mus muscles. The efﬁciency of CXCR4 or CXCR7 down
195 regulation was assessed by qRT-PCR and Western-blot.
Quantiﬁed real time PCR (qRT-PCR)
Total RNA was isolated from primary myoblasts, WJ-
MSCs, and ESCs usingmirVana Isolation Kit (Life Technlo-
gies), according to the manufacturer’s protocol. RNA was
200 extracted from biological triplicates (3 independent cell cul-
tures per each experiment). Two hundred 50 ng of RNA
from each sample was reverse-transcribed using the Super-
Script II Reverse Transcriptase (Life Technologies)
according to the manufacturer’s protocol. Next, mRNA
205levels were examined using Quantitative real-time PCR
analysis (qPCR) with TaqMan assays (Life Technologies)
for the following genes: CXCR4 [Mm01996749], CXCR7
[Mm02619632], Rac-1 [Mm01331626], Cdc42
[Mm01194005], focal adhesion kinase (FAK)
210[Mm00552827], and actin [Mm01268569]. Hypoxanthine
phosphoribosyltransferase 1 (Hprt1) [Mm01545399] was
used as the reference gene. All reactions were performed in
triplicates. qPCR was performed with the TaqMan Gene
Expression Master Mix (Life Technologies) using LightCy-
215cler 480 (Roche Applied Sciences) according to manufac-
turer’s instruction. The conditions of RT-qPCR were as
follows: reverse transcription: 25C for 10 min, 42C for
60 min, 85C for 5 min, qPCR: 50C for 2 min, template
denaturation 95C for 10 min, 45 cycles of 95C for 15 sec
220and 60C for 60 sec. Threshold-cycle (Ct) values of the ana-
lyzed amplicons were determined with LightCycler 480
Software (Roche Applied Science). Expression levels were
calculated with 2-(DCT) formula using relative quantiﬁcation
tool in LightCycler 480 Software. Expression levels and
225standard deviations for each gene was visualized as the col-
umn charts using GraphPad Software (La Jolla, CA, USA).
Reference gene Hprt1 displayed high expression stability.
Results were analyzed using using GraphPad Software and
non-paired t-test was performed to compare treated with
230the control cells. The differences were considered statisti-
cally signiﬁcant when p< 0.05 (marked with asterisks).
Cell proliferation assay
Primary myoblasts, WJ-MSCs, and ESCs were incubated in
0.5 mM carboxyﬂuorescein succinimidyl ester (CFSE, Life
235Technologies) in PBS at 37C for 10 min. Cells were rinsed
in PBS and cultured for 2 d in the culturemedium appropri-
ate for each cell type, under standard conditions. Next, cells
were rinsed in PBS and subjected to ﬂow cytometry analysis
(BD FACSCALIBUR, BD Biosciences) using CellQuestPro
240software. Unlabeled cells (negative control) and cells ana-
lyzed directly after labeling with CFSE (positive control)
were included into each experiment. Three independent
experiments were performed. Results were analyzed using
GraphPad Software and non-paired t-test was performed to
245compare treated with the control cells. The differences were
considered statistically signiﬁcant when p < 0.05 (marked
with asterisks).
Migration assay
Migration of myoblasts, WJ-MSCs, and ESCs was ana-
250lyzed using scratch wound healing assay.37 Brieﬂy, cells
were plated in the culture dish and cultured until they
reached 90% of conﬂuency. Next, the cells were
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scratched from the plate using plastic tip to create the
“wound.” The wound healing manifested by the ability
255 of the cells to reﬁll the created gap was monitored after
48h of culture. Three independent experiments were
performed. Results were analyzed using using GraphPad
Software and non-paired t-test was performed to
compare treated with the control cells. The differences
260 were considered statistically signiﬁcant when p < 0.05
(marked on charts with asterisks).
Analysis of Rac-1 and Cdc42 activity
Primary myoblasts, ESCs and WJ-MScs were cultured as
described above. Thirty min after Sdf-1 treatment cells
265 were lysed in culture dishes, lysates collected and frozen
in liquid nitrogen. Active Cdc42 and Rac-1 were ana-
lyzed using the G-LISA activation assay kit (Cytoskele-
ton, Inc.) according to the manufacturer’s instructions.
The chemiluminescence signal was detected using the
270 mQuant (Biotek Instruments) microplate reader. Three
independent experiments were performed. Results were
analyzed using GraphPad Software and non-paired t-test
was performed to compare treated with the control cells.
The differences were considered statistically signiﬁcant
275 when p < 0.05 (marked on charts with asterisks).
Microarray analysis
ESCs were cultured and either treated with Sdf-1 or
transfected with Silencer Select Pre-designed siRNA (Life
Technologies) complementary to mRNAs encoding
280 either CXCR4 (ID:s64091) or CXCR7 (ID:s64124) as
described above. Total RNA was isolated using mirVana
Isolation Kit (Life Technlogies). Next, its integrity was
checked with 2100 Bioanalyzer (Agilent Technologies)
using RNA 6000 NAno LAb Chip kit (Agilent Technolo-
285 gies). All RNA samples had integrity number above 8.5.
100 ng of total RNA for each sample was biotin labeled
with the TargetAmpTM-Nano Labeling Kit for Illumina
Expression BeadChip (Epicentre Biotechnologies).
Labeled RNA was puriﬁed with RNeasy MinElute
290 Cleanup Kit (Qiagen) and hybridized onto MouseRef-8
v2.0 Expression BeadChip (Illumina Inc.) according to
manufacturer’s instructions. Arrays were scanned with
an HiScanSQ System (Illumina Inc.). Raw data were
imported to GenomeStudio (Illumina) and the average
295 signal intensities were analyzed in Partek Genomic Suite
(Partek, Inc.) v. 6.6 after quantile normalization and
Log2 transformation. Qualitative analysis was per-
formed, e.g. Principal Component Analysis, in order to
identify outliers and artifacts on the microarray. After
300 quality check the 2-way ANOVA (Analysis of Variance)
model by using Method of Moments38 was performed
on the data and lists of signiﬁcantly and differentially
expressed genes between biological variants (with the
cutoff values: p-value < 0.05, ¡1.3>Fold Change>1.3)
305were created. Fisher’s Least Signiﬁcant Difference (LSD)
was used as the contrast method39 to compare: ES-Cxcr4
(ESCs transfected with siRNA complementary to
CXCX4 mRNA) vs ES-Sdf-1 (ESCs treated with Sdf-1)
and ES-Cxcr7 (ESCs transfected with siRNA comple-
310mentary to CXCX7 mRNA) vs ES-Sdf-1. Unsupervised
hierarchical clustering was performed on the selected
lists to in order to ﬁnd genes and samples with similar
proﬁles. Gene networks were created by interposing the
results onto the database of Ingenuity containing infor-
315mation about gene functions with the use if Ingenuity
Pathway Analysis tool.
Muscle injury and cells transplantation
To induce regeneration of skeletal muscles, 3 month old
male BALB/c mice were anesthetized and their gastrocnie-
320mus muscles were injected with 50 ml of cardiotoxin (CTX)
from Naja mossambica (10 mM in PBS, Sigma-Aldrich).
After the procedure mice were kept under standard condi-
tions with free access to food and water. Twenty four hours
later control cells, Sdf-1 treated cells, or cells in that expres-
325sion of Cxcr4 or Cxcr7 was silenced were injected into
injured muscles. The number of transplanted cells varied,
i.e. 0.5 million of myoblasts, 0.2 million of WJ-MSCs or
1 million of ESCs, suspended in 50 ml of PBS, was trans-
planted. Moreover, regenerating gastrocnemius muscle was
330injected with Sdf-1 (100 ng per 20 ml of 0.9% NaCl ) or
20 ml of 0.9% NaCl (saline treated muscles served controls).
Sdf-1 and NaCl was injected at the opposite ends of the
muscles than the transplanted cells. After 7 or 14 d after
injury, i.e., days of regeneration, muscles were dissected and
335analyzed (immunocytochemistry and histochemistry).
Localization of transplanted cells within the muscle was
based on the expression of appropriate markers. Satellite
cells, from which primary myoblasts were derived, were iso-
lated from 3-month old C57Bl6N male mice carrying the
340lacZ transgene in the ROSA26 locus. WJ-MSCs were local-
ized on the basis of human nuclear antigen. ESCs were local-
ized on the basis of the expression of H2B-GFP.
Immunocytochemistry
Selected antigens were immunolocalized in in vitro cultured
345cells, isolated at day 7 of regeneration muscle ﬁbers, as well
as in muscle sections (cross and longitudinal). Cells or iso-
lated muscle ﬁbers were ﬁxed with 3% PFA for 10 min,
washed with PBS and stored in 4C. Muscles were dissected
7 or 14 d after injury and cells transplantation. They were
350frozen in isopentane cooled with liquid nitrogen, transferred
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into¡80C, and cut into 7 mm-thick sections with cryomi-
crotome (Microm HM505N) and stored in 4C. Cryosec-
tions were hydrated in PBS, ﬁxed in 3% PFA, and washed
with PBS. To obtain longitudinal sections dissected muscles
355 were ﬁxed with Bouin’s solution, dehydrated and embed
into parafﬁn blocks. Parafﬁn blocks were cut for 9mm-thick
slices and placed on covered with 0.5% gelatin in water glass
slides and then dried in 40C. Parafﬁn sections were stored
in 4C and rehydrated before immunolocalization.
360 Next, cells or muscle sections were permeabilized with
0.1% Triton X-100/PBS (Sigma-Aldrich), and incubated
with 0.25% glycine (Sigma-Aldrich). Non-speciﬁc binding
of antibodies was blocked with 3% bovine serum albumin
(BSA, Sigma-Aldrich) supplementedwith 2% donkey serum
365 (Sigma-Aldrich) in PBS, at room temperature, for 1h. Next,
samples were incubated for 2 h with primary antibodies
diluted 1:100 in 3% BSA in PBS, overnight, washed with
PBS, and incubated at room temperature with secondary
antibodies diluted 1: 200 in 1.5% BSA in PBS. After washing
370 with PBS, cell nuclei were visualized by incubation with
DraQ5 (Biostatus Limited) diluted 1:1000 in PBS for
10 min. Specimens were mounted with Fluorescent Mount-
ing Medium (Dako Cytomation). After the procedure was
completed samples were analyzed using confocal micro-
375 scope Axiovert 100M (Zeiss) and LSM 510 software. The
following primary antibodies were used: chicken polyclonal
anti-b-galactosidase (Abcam), mouse monoclonal anti-
human nuclear antigen (Abcam), mouse monoclonal anti-
Green Fluorescent Protein (GFP) (Abcam), rabbit
380 polyclonal anti-Myod1 (Abcam), mouse monoclonal anti-
Cdc42 (SantaCruz Biotechnology), rabbit polyclonal anti-
Rac-1 (SantaCruz Biotechnology), rabbit polyclonal
anti-FAK (SantaCruz Biotechnology), and rabbit polyclonal
anti-laminin (Sigma-Aldrich). The following secondary
385 antibodies were used: anti-mouse igG Alexa Fluor 488, anti-
rabbit igG Alexa Fluor 566, anti-rabbit igG Alexa Fluor 488,
and anti-chicken igG Alexa Fluor 488. All secondary anti-
bodies were purchased from Life Technologies. Actin cyto-
skeleton was localized using falloidin conjugated with
390 TRITC (Sigma). Three independent experiments were
performed for each analysis.
Western blotting
Proteins were isolated from cells or gastrocnemius muscles
using cOmplete Lysis-M EDTA-free kit (Roche Applied Sci-
395 ence). Twenty-ﬁvemg of total protein lysate were denatured
by boiling in Laemmli buffer, separated using SDS-Page
electrophoresis, and transferred to PVDF membranes
(Roche Applied Science). The membranes were blocked
with 5% Blotto (BioRad)/TBS for 1h and incubated with pri-
400 mary antibodies diluted 1:2000 in 5% Blotto (BioRad)/TBS,
at 4C, overnight, followed by secondary antibodies diluted
1:20000, at room temperature, for 2 h. Next, protein bands
were visualized with SuperSignal West Pico Chemilumines-
cent Substrate (Thermo Scientiﬁc) and exposed to chemilu-
405minescence positive ﬁlm (Amersham Hyperﬁlm ECL, GE
Healthcare). The obtained results were analyzed with Gel-
Doc2000 using Quantity One software (BioRad). The den-
sity of examined bands was compared to density of tubulin
bands. The following primary antibodies were used: rabbit
410polyclonal anti-Cxcr4 (Abcam), rabbit polyclonal anti-
Cxcr7 (Abcam), rabbit polyclonal anti-pFAK (Cell
Signaling), rabbit polyclonal anti-FAK (SantaCruz Biotech-
nology), mouse monoclonal anti-Cdc42 (SantaCruz Bio-
technology), rabbit polyclonal anti-Rac-1 (SantaCruz
415Biotechnology), mouse monoclonal anti-actin (Abcam),
and mouse monoclonal anti-tubulin (Sigma-Aldrich). Sec-
ondary antibodies used were: peroxidase-conjugate rabbit
anti-mouse igg (Sigma-Aldrich) and peroxidase-conjugate
goat anti-rabbit igg (Sigma-Aldrich). Three independent
420experiments were performed.
Flow cytometry analysis
Gastrocnemius muscles that received ESCs constitutively
expressing histone H2B-GFP were isolated at day 7 and 14
of regeneration. Next, they were digested with 0.15% pro-
425nase (SigmaAldrich) inHam’s F12medium (Life Technolo-
gies) buffered with 10 mM HEPES (Life TEchnoloﬁes),
containing 10% fetal calf serum (FCS), at 37C, for 1.5 h.
Obtained cell suspension was ﬁltered through 40 mm cell
strainer. Then, cells were ﬁxed in a 3% PFA in PBS, washed
430with PBS, and analyzed with FACSCalibur (Becton-Dickin-
son) equipped with a 488-nm argon laser to detect GFP sig-
nal. The cells were also incubated with rabbit polyclonal
anti-Myf5 antibody (Abcam) diluted in 3% BSA in PBS
1:100, at room temperature, for 1 h, followed by secondary
435antibody anti-rabbit igG Alexa Fluor 566. Three data
parameters were acquired and stored: FSC, SSC and ﬂuores-
cence 1 – FL1 (ﬂuorescein isothiocyanate, FITC). CellQuest
application, version 1.2, was used for the analysis. Three
independent experiments were performed. Results were
440analyzed GraphPad Software and non-paired t-test was
performed to compare treated with the control cells. The
differences were considered statistically signiﬁcant when
p< 0.05 (marked on charts with asterisks).
Results
445Sdf-1 induces stem cells migration but
not proliferation
We analyzed primary myoblasts, WJ-MSCs, or ESCs which
were treated with Sdf-1 alone or transfected with siRNA
complementary to mRNAs encoding either Cxcr4 or Cxcr7
CELL ADHESION & MIGRATION 5
450 and treated with Sdf-1, along with control, i.e. untreated
cells. The Cxcr4 or Cxcr7 silencing assessed at mRNA level
was proved to be efﬁcient. siRNA complementary to Cxcr4
mRNAdecreased the level of this transcript to 28%C/¡ 8%
in primary myoblasts, 49% C/¡ 16% in WJ-MSCs, and to
455 34% C/¡ 8% in ESCs, as compared to control, i.e., cells of
each type that where neither treated with Sdf-1 nor trans-
fected with siRNAs (Fig. 1A). siRNA complementary to
mRNA encoding Cxcr7 decreased the level of Cxcr7 tran-
scripts to 34% C/¡ 11% in primary myoblasts, 38% C/¡
460 18% inWJ-MSCs and 41%C/¡ 13% in ESCs, as compared
to control (Fig. 1A). Sdf-1 treatment did not signiﬁcantly
change the level of Cxcr4 or Cxcr7 mRNA (Fig. 1A). The
changes in CXCR4 and CXCR7 level in treated cells were
also pronounced at protein level (Fig. 1B).
465 Scratch migration assay revealed that in the response
to Sdf-1 gradient primary myoblasts, WJ-MSC and ESCs
migrate more effectively (Fig. 2A). Migration of all types
of examined cells depended on Cxcr4 receptor - silencing
of its expression decreased this process (Fig. 2A). Cxcr7
470 silencing did not signiﬁcantly impact at the cell migra-
tion in performed assay. Next, we tested whether Sdf-1
controls the ability of primary myoblasts, WJ-MSCs, and
ESCs to proliferate. CFSE test allowed us to estimate the
proportion of cells that did not divide, divided once or
475 more than twice. It proved that Sdf-1 treatment did not
change myoblasts, WJ-MSCs, as well as ESCs prolifera-
tion rate. Neither Cxcr4 nor Cxcr7 expression silencing
affected primary myoblasts and WJ-MSCs divisions
(Fig. 2B). Interestingly, Cxcr7 silencing signiﬁcantly
480increased ESCs proliferation (Fig. 2B).
The signaling pathways in actin organization in
stem cells after Sdf-1 treatment
Next, we analyzed the changes in actin cytoskeleton organi-
zation and which signaling pathways were involved in the
485activation of the analyzed cells migration in the response to
Sdf-1. We chose to analyze Cdc42 (cell division control pro-
tein 42), Rac-1 (Ras-Related C3 Botulinum Toxin Substrate
1), and focal adhesion kinase (FAK), i.e. the factors known
to participate in the processes associated with cell migration
490such as actin polymerization and focal contacts forma-
tion.40-42 After Sdf-1 stimulation themorphology of the cells
and organization of actin cytoskeleton changed, i.e., all ana-
lyzed cells formed numerous stress ﬁbers and ﬁlopodia
(Fig. 3A). In Sdf-1 treated cells the actin ﬁlaments were
495more abundant (Fig. 3A). This effect was reversed by Cxcr4
silencing, what correlated with the decrease in actin expres-
sion at mRNA and protein levels (Fig. 3B and C). The SCs
and WJ-MSCs in that CxCr4 expression was silenced were
Figure 1. The Cxcr4 and Cxcr7 level in in vitro cultured primary myoblasts, WJ-MSCs, and ESCs 48h after transfection with siRNA and Sdf-1 treat-
ment. (A) The level of mRNA encoding Cxcr4 and Cxcr7. Obtained data is presented as mean§ standard deviation. Student’s non-paired t-test
was used for statistical analyses. Asterisk marks signiﬁcant differences (P< 0.05). (B) Western blotting of Cxcr4, Cxcr7, and tubulin.
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characterized by changes in Cdc42, Rac-1 and FAK localiza-
500 tion (Fig. 3D and E).
However, Sdf-1 did not impact at the levels of Cdc42,
Rac-1, and FAK proteins in primary myoblasts, WJ-MSCs,
or ESCs (Fig. 4A). Silencing of Cxcr4 or Cxcr7 expression
slightly decreased the level of Cdc42 protein (Fig. 4A).
505 Importantly, Sdf-1 caused the signiﬁcant changes in the
activity of studied proteins (Fig. 4A and B). The activity of
Cdc42 and Rac-1 GTPases was higher in Sdf-1 treated myo-
blasts, WJ-MSCs, and also ESCs, as compared to the
untreated cells (Fig. 4B). Silencing of Cxcr4 but not Cxcr7
510 abolished the impact of Sdf-1 at the activity of Cdc42 and
Rac-1 GTPases. As far as active, phosphorylated form of
FAK (pFAK), is concerned it was detectable in control myo-
blasts, WJ-MSCs, and ESCs (Fig. 4A). Sdf-1 caused increase
in the level of pFAK in myoblasts andWJ-MSCs, but not in
515 ESCs. However, in all studied cell types the effect of Sdf-1 on
FAK phosphorylation was lost when expression of both its
receptors, i.e. Cxcr4 and Cxcr7, was silenced (Fig. 4A).
Changes in transcription proﬁle in ESCs after
Sdf-1 treatment
520 To analyze the changes in the transcriptome provoked by
Sdf-1 we decided to use ESCs because in these cells the
changes in morphology and cytoskeleton organization was
the best pronounced after Sdf-1 treatment. mRNA isolated
from control ESCs, as well as cells that were Sdf-1 treated,
525 Sdf-1 treated and transfected with siRNA complementary
to mRNAs encoding either Cxcr4 or Cxcr7, was analyzed
using microarray technique (Fig. 5). Analysis of variance
(ANOVA) allowed to create lists of genes signiﬁcantly
down-regulated in ESCs that were Sdf-1 treated and
530transfected with appropriate siRNA, as compared to cells
treated only with Sdf-1 (with the cutoff values: p-value<
0.05, ¡1.3>Fold Change>1.3). This analysis revealed that
Sdf-1, acting via Cxcr4 receptor, regulates the expression of
90 transcripts, while acting via Cxcr7 receptor affects the
535expression of 113 transcripts (Fig. S1). Using Ingenuity
Pathway Analysis we showed that Sdf-1 impacts at the
expression ofmany genes encoding proteins engaged in cells
adhesion and migration (Fig. 5), including transcripts
encoding proteins engaged directly or indirectly in actin and
540adhesion proteins expression. Sdf-1 acting via Cxcr4, but
not Cxcr7, regulates the expression of mRNA encoding
adhesion proteins such as tetraspanin CD9 and ADAM9 (a
disintegrin and metalloproteinase 9). Sdf-1 acting via Cxcr4
inﬂuences the expression of transcripts encoding cytoskele-
545ton proteins present in skeletal muscle ﬁbers, such as actin
or a actin (ACTA1). Activation of this signaling pathway
also induced the expression of calpain small subunit 1
(CAPNS1) that belongs to the family of calcium-dependent,
non-lysosomal cysteine proteases. Sdf-1 acting via Cxcr7
550impacted the levels of mRNAs encoding F-actin and
ACTA1. It also reduced the expression of mRNAs encoding
calpains, such as calpain 5 (CAPN 5) and CAPNS1. Sum-
marizing, transcriptome analysis conﬁrmed important role
of Sdf-1 in the activation ofmigration and allowed us to pin-
555point and distinguish the targets of pathways activated by
Sdf-1 binding to Cxcr4 or Cxcr7.
Regeneration of injured skeletal muscles treated
with Sdf-1 and stem cells
Next, we decided to analyze if Sdf-1 pretreatment of trans-
560planted cells or Sdf-1 co-injection with transplanted cells
Figure 2. Sdf-1 impact at in vitro cultured primary myoblasts, WJ-MSCs, and ESCs migration and proliferation. (A) Proportion of invaded
area calculated from the results of scratch wound assay. Analysis was performed at day second after the scratch wound formation. (B)
Results of CFSE test documenting the proliferation rate of studied cells. Analysis was performed after 2 d of culture subsequently CFSE
staining. Obtained data is presented as mean § standard deviation. Student’s non-paired t-test was used for statistical analyses. Asterisk
marks signiﬁcant differences (P < 0.05).
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could improve participation of stem cells in muscle regener-
ation. Again we also focused at the role of Cxcr4 and Cxcr7
in the migration of tested cells in regenerating muscle. Con-
trol, i.e., untreated primary myoblasts, WJ-MSCs, or ESCs,
565 as wells as cells treated with Sdf-1 alone or treated with Sdf-
1 and transfected with siRNA complementary to mRNAs
encoding either Cxcr4 or Cxcr7 were transplanted to control
muscles injectedwith 0.9%NaCl (saline) ormuscles injected
with Sdf-1 in 0.9% NaCl (Fig. 6). Onemuscle of eachmuscle
570pair was injectedwith saline, while another, i.e. contralateral,
with Sdf-1. Importantly, Sdf-1 was injected at the opposite
end of themuscle in the relation to the site of cells transplan-
tation (approximately 1 cm distance). Sdf-1 was co-injected
with transplanted cells.
575First, we focused at the morphology of all groups of
treated muscles, followed the localization of transplanted
cells, as well as, the efﬁciency of their migration and muscle
homing (Fig. 7). Primary myoblast were identiﬁed as
Figure 3. Sdf-1 impact at actin, FAK, Rac-1 and Cdc42 in in vitro cultured primary myoblasts, WJ-MSCs, and ESCs. (A) Immunolocalization
of actin (red - actin, blue - chromatin). (B) The level of mRNA encoding actin. Obtained data is presented as mean § standard deviation.
Student’s non-paired t-test was used for statistical analyses. Asterisk marks signiﬁcant differences (P < 0.05). (C) Western blotting of
actin in ESCs. (C) Localization of FAK, Rac-1 and Cdc42 in primary myoblasts (blue – chromatin, red – immunolocalization of actin, green
– immunolocalization of studied proteins). (D) Localization of FAK, Rac-1 and Cdc42 in WJ-MSCs (blue – chromatin, red – immunolocali-
zation of actin, green – immunolocalization of studied proteins).
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b-galactosidase positive cells, humanWJ-MSCs on the basis
580 of human nuclear antigen immunolocalization, and ESCs
on the basis of histone H2B-GFP ﬂuorescence. The efﬁ-
ciency of the participation of transplanted cells in themuscle
regeneration was assessed on the basis of the number of cells
able to home injured muscle and/or to form new muscle
585 ﬁbers. Transplanted primary myoblasts formed new muscle
ﬁbers with the highest efﬁciency, as compared to other cells
analyzed (Fig. 7A and B). Control primary myoblasts trans-
planted to muscles injected with saline participated in the
formation of 4.7% C/¡ 3% muscle ﬁbers. In Sdf-1 treated
590 muscles this proportion reached 8.2% C/¡ 3.5%. Finally,
Sdf-1-treated myoblasts injected to Sdf-1-injected muscles
participated in the formation of 12.1% C/¡ 5.5% ﬁbers
(Fig. 7A and B). Silencing of Cxcr4 expression signiﬁcantly
decreased the number of myoﬁbers formed with the partici-
595 pation of transplanted myoblasts (Fig. 7B). Silencing of
Cxcr7 expression did not signiﬁcantly change the number
of myoﬁbers formed with the participation of transplanted
myoblasts (Fig. 7B). Thus, co-injection of myoblasts and
Sdf-1 improved participation of myoblast in formation of
600newmyoﬁbers.
TheWJ-MSCs transplanted into injuredmuscles, control
or Sdf-1 injected, only very rarely were found within regen-
erating tissue. Only few of them were able to participate in
formation of new muscle ﬁbers (data not shown). On the
605other hand, ESCs were able to home regenerating tissue and
were easily detectable betweenmuscle ﬁbers. However, these
cells also only very rarely were found to participate in the
formation of muscle ﬁbers. In control, saline-injected
muscles most of the control, untreated ESCs formed aggre-
610gates surrounded with muscle ﬁber basal lamina. Only sin-
gle cells were localized along basal lamina. The localization
of ESCs changed when muscles were injected with Sdf-1.
Under such conditions ESCs were able to migrate and local-
ize along muscle ﬁber basal lamina. In this case they very
Figure 4. Sdf-1 impact at FAK, Rac-1 and Cdc42 level and activation in vitro cultured primary myoblasts, WJ-MSCs, and ESCs. (A) Western
blotting of Cxcr4, Cxcr7, FAK, phosphorylated FAK (pFAK), Rac-1, Cdc42, and tubulin. (B) The activity of Rac-1 and Cdc42 in primary
myoblasts, WJ-MSCs and ESCs. Obtained data is presented as mean § standard deviation. Student’s non-paired t-test was used for
statistical analyses. Asterisk marks signiﬁcant differences (P < 0.05).
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Figure 5. Sdf-1 impact at global gene expression in in vitro cultured ESCs. (A) Transcription proﬁle of genes in ESCs. Blue color indicates
low and red color indicates high expression levels of mRNA transcripts. (B) Gene networks created by interposing the results onto
database of Ingenuity containing information about the gene function with the use of Ingenuity Pathway Analysis tool.
Figure 6. The experimental design of in vivo analyses.
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Figure 7. The localization of primarymyoblasts, WJ-MSCs, and ESCs after transplantation to injured gastrocnemiusmuscle. (A) The localization of
transplanted primary myoblasts expressing b-galactosidase in cross section of muscle at day 7 of regeneration (green - b-galactosidase, blue –
chromatin, red – immunolocalization of laminin). (B) The proportion of muscle ﬁbers formed with the participation of transplanted myoblasts in
cross sections of muscle at day 7 of regeneration (nD 5). (C) The localization of transplanted ESCs expressing Green Fluoresent protein (GFP) in
longitudinal section of muscle at day 7 of regeneration (green - GFP, blue – chromatin, red – immunolocalization of laminin). (D) The localization
of mononucleated cells at muscle ﬁber isolated from skeletal muscle engrafted with ESCs expressing GFP analyzed at day 7 of regeneration
(green –GFP, red – immunolocalization of GFP using anti-GFP antibody, blue – immunolocalization of Myod1, yellow - chromatin). (E) Proportion
of ESCs expressing GFP in the population of mononucleated cells isolated from themuscle at day 7 and 14 of regeneration (nD 3). (F) Proportion
of ESCs expressing Myf5 in the population of GFP expressing ESCs (nD 3). FACS analysis of results is presented as mean§ standard deviation.
Student’s non-paired t-test was used for statistical analyses. Asterisk marks signiﬁcant differences (P< 0.05).
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615 rarely formed aggregates and were mostly visible as a single
cells (Fig. 7C). Similar behavior characterized Sdf-1 treated
ESCs transplanted either into control or Sdf-1 treated
muscles. Silencing of Cxcr4 but not Cxcx7 expression led to
the decrease of ESCsmigration. As a result transplanted cells
620 were localized mostly in aggregates. FACS analysis allowed
us to verify the proportion of ESCs present within the mus-
cle at days 7 and 14 of regeneration. Generally, in the popu-
lation of mononucleated cells isolated from the regenerating
muscle we were able to detect between 0.32% and 1.65% of
625 ESCs at day 7 and only 0.08% – 0.64% of ESCs at day 14
(Fig. 7E). ESCs were identiﬁed on the basis of histone H2B-
GFP ﬂuorescence. At day 7 of regeneration the proportion
of ESCs detectable within the muscles injected with saline
was 0.37%–1.44% and it reached 0.32%–1.65% in the
630 muscles treated with Sdf-1. At day 14 of regeneration the
proportion of ESCs was very low (less than 0.64%) and it
was comparable between control and Sdf-1 treated muscles.
Silencing of Cxcr4 or Cxcr7 expression did not decreased
the proportion of ESCs present in regenerating muscles
635 (Fig. 7E). Regardless of their localization, ESCs cells very
rarely expressed myogenic transcription factors, such as
Myod1, as demonstrated by immunolocalization (Fig. 7D).
At day 7 of regeneration up to 0.01% of GFP positive cells
i.e., ESCs isolated from the muscles expressed Myf5, as
640 shown by FACS analysis (Fig. 7F). At day 14 of regeneration
the proportion of Myf5 expressing ESCs reached 0.17%.
Sdf-1 did not change this proportion. Summarizing, Sdf-1
improved the ability of ESCs to migrate in injured muscle.
However, these cells only very rarely initiated myogenic
645 differentiation when transplanted into injuredmuscle.
Discussion
Our study shows that Sdf-1, acting via Cxcr4, increased pri-
mary myoblast, WJ-MSC, and ESCs ability to migrate in
vitro. Except increasing the expression of CD924 Sdf-1 also
650 impacts at the expression and activation of other proteins
engaged in cell adhesion and migration. Sdf-1 treatment
also resulted in the activation of FAK, i.e. non-receptor tyro-
sine kinase present in focal contacts composed of proteins
anchoring integrins with actin cytoskeleton [reviewed in
655 ref.40]. Sdf-1 dependent FAK activation could be achieved
by stimulating both Cxcr4 and Cxcr7 receptors. Active FAK
kinase is a key component of many signal transduction
pathways [reviewed in ref.44]. However, from our point of
view, the role of FAK in the activation of cell motility is the
660 most important one [reviewed in ref.45]. Among such func-
tions of FAK could be its positive impact at the MMP-2 and
¡9 (matrix metalloproteinases-2 and ¡9) expression and
activity inﬂuencing extracellular matrix degradation during
cells migration.46,47 Next, FAK signaling controls the forma-
665 tion and turnover of focal contacts47 and also activates Rho
GTPases leading to actin stress ﬁber formation.48 In our
study, Sdf-1 treatment of cells led also to the activation of
GTPases: Rac-1 and Cdc42 belonging to Rho GTPases fam-
ily. Importantly, activation of these proteins depended only
670at Cxcr4. It was shown previously that Rac-1 mediates actin
polymerization in lamellipodia at the front ofmigrating cells
and Cdc42 induced actin polymerization in ﬁlopodia and
invadopodia.49
Our study also reveals the differences in cell signaling
675mediated by Sdf-1 - Cxcr4 andCxcr7 pathways. Cxcr4 inter-
acts with Sdf-1 but Cxcr7 except Sdf-1 also binds chemokine
I-TAC (CXCL11) [reviewed in ref.50]. By silencing each of
these receptors we were able to distinguish which one is
involved in the regulation of certain genes. Thus, in ESCs
680expression of CD9 is regulated via Sdf-1 activating Cxcr4,
but not Cxcr7, what was in agreement with our previous
results documenting Sdf-1 dependent expression of CD9 in
C2C12 myoblasts, bone marrow derived MSC, and ESCs.24
Here we showed that also expression of ADAM9 is induced
685in ESCs by Sdf-1 in Cxcr4 dependent manner. The role of
ADAM-9 in the cell migration was previously documented
for keratinocytes and ﬁbroblasts.51,52 Analysis of keratino-
cytes showed that ADAM-9 regulates cells migration by
interaction with integrin b1 and regulation of MMPs syn-
690thesis.51 Thus, activation of FAK, Rac-1, and Cdc42, as well
as induction of CD9 and ADAM-9 expression, underlay the
ability of studied cells tomigrate.
We show that Sdf-1, acting viaCxcr4, increasedmyoblast
ability to migrate in vitro and participate in the formation of
695new muscle ﬁbers in vivo when transplanted intramuscu-
larly. The effect of Sdf-1 treatment was manifested better
whenmyoblasts and Sdf-1 were co-injected thenwhenmyo-
blast were pre-treated with Sdf-1. On the other hand, it was
shown that the pre-incubation of myoblasts with bFGF or
700Concanavalin A was shown to increase the efﬁciency of
myoblasts transplantation.53-55 The effect we observed was
also similar to that documented for other cell types, such as
mesoangioblasts, which pre-treatment with Sdf-1 or tumor
necrosis factor a (TNF-a) enhanced their delivery and led
705to a complete reconstitution of skeletal muscles in mice that
serve as a mouse model of severe muscular dystrophy.56 In
our hands the pre-treatment of ESCs with Sdf-1 or co-injec-
tion of ESCs and Sdf-1 into skeletal muscles increased their
ability to migrate within the regenerating tissue. Previously,
710we showed that ESCs pretreatment improved the ability of
ESCs to migrate and fuse with myoblasts in vitro.24 Since,
Sdf-1 increased the expression of CD9 in ESCs we postu-
lated that it might facilitate the fusion.24 Currently, we also
documented that Sdf-1 promoted migration of ESCs within
715injured muscle and stimulated these cells to align in the
manner characteristic for fusing myoblasts. Unfortunately,
it did not affect the ESCs ability to initiate myogenic differ-
entiation and fusion withmyoblasts in vivo. However, it was
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previously shown that in order to inducemyogenic differen-
720 tiation of ESCs one has to either overexpress myogenic fac-
tors such as MyoD, Pax3 or Pax7 or treat the them with
precisely designed cocktail of factors [reviewed in ref.33].
ESCs that were not subjected to such treatments fail to effec-
tively differentiate and fuse with myoblasts most probably
725 due to the fact that they do not initiate the expression of M-
cadherin or vascular cell adhesion molecule (V-CAM1) that
are also crucial for fusion.25
MSCs isolated from Wharton jelly (WJ-MSCs), as
well as adherent fraction of human umbilical cord blood
730 cells, i.e., the cells that constitute the subpopulation
enriched in MSCs, were shown by us to be able to follow
myogenic program both in vitro and in vivo.26,57 In our
hands WJ-MSCs were able to colonize injured skeletal
muscle and, with frequency of 5.3%, participate in the
735 formation of new muscle ﬁbers. Pre-treatment of WJ-
MSCs with Sdf-1 did not impact their ability to form
new muscle ﬁbers but signiﬁcantly increased muscle
mass. Interestingly, in vitro these cells manifested myo-
genic potential and formed hybrid myotubes with
740 C2C12 myoblasts.26 Currently we documented that Sdf-
1 treatment induced migration of WJ-MSC in vitro.
However, this stimulation was not sufﬁcient to improve
their participation in the muscle reconstruction. Our
result is in bright contrast to other study which showed
745 that MSCs isolated from rat or human bone marrow par-
ticipated in the formation of as many as 60–70% of new
muscle ﬁbers and restored expression of dystrophin in
mdx mice muscles.58 Thus, MSCs isolated form varied
sources could differ in their myogenic potential.
750 Summarizing, Sdf-1 improved the ability of primary
myoblasts and ESCs to migrate within the injured muscle.
Moreover, injected intramuscularly Sdf-1 stimulated the
transplanted primary myoblasts to participate in the forma-
tion of new muscle ﬁbers. Mechanisms controlling cells
755 migration activated by Sdf-1 rely at Cxcr4-dependent signal-
ing pathways leading to the activation of proteins engaged in
the focal contacts formation and actin polymerization, such
as FAK, Rac-1, and Cdc42, as well as the expression of CD9
andADAM-9. Sdf-1 - Cxcr7 interactions change the expres-
760 sion and activation of proteins engaged in cell migration,
however, these changes does not result in the alternation of
cell motility. Sdf-1 certainly improves migration of trans-
planted cells, however, fails to efﬁciently induce their myo-
genic differentiation. However, one has to remember that,
765 as we shown previously, it greatly impacts at the homing of
endogenous stem cells and by doing that improves muscle
regeneration.23,59
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